132 results about "Glidant" patented technology

The invention discloses granules of a composition containing rhizoma polygonati. The granules comprise the following components in percentage by weight: 30%-50% of composition dry paste powder, 38%-58% of a filling agent, 0.1%-20% of an adhesive and 0.1%-2% of a flow aid, the composition comprises rhizoma polygonati, fructus lycii, flos chrysanthemi and radix glehniae. Wherein the filling agent is dextrin; wherein the adhesive is maltodextrin or povidone; wherein the flow aid is colloidal silicon dioxide. According to the composition disclosed by the invention, proper auxiliary materials and an adding mode thereof are selected, so that the inherent properties of the original extract are improved, the extract is not easy to soften, the caking tendency caused by moisture absorption or heat absorption among particles is avoided, and the caking probability is reduced.

The invention relates to a doxepin hydrochloride tablet. The doxepin hydrochloride tablet is prepared from doxepin hydrochloride, polyethylene glycol 6000, a filling agent, a disintegrating agent, a flow aid and a lubricating agent. The preparation method comprises the following steps: heating and melting polyethylene glycol 6000, adding a doxepin hydrochloride raw material according to a prescription proportion, and uniformly stirring and mixing; and after complete melting, rapidly cooling and solidifying to form a solid dispersion. And after curing, drying in a drying oven, crushing and sieving. And uniformly mixing the crushed particles with the filler and the lubricant, and directly tabletting. The doxepin hydrochloride has high hygroscopicity, is unstable to damp and heat and easily generates a large amount of impurities under strong oxidation conditions, the doxepin hydrochloride is firstly prepared into a solid dispersion and then is directly compressed, so that the medicine is highly dispersed in a carrier material in the states of molecules, colloids, amorphous forms, microcrystals and the like, and the effect of wrapping the medicine is achieved by controlling the ratio of the medicine to the carrier. Direct contact between the medicine and air is avoided, so that the problems of hygroscopicity and instability of the medicine are solved, and the product stability is improved.

The present invention discloses a tofacitinib citrate sustained-release tablet preparation and a preparation method thereof, which belongs to the technical field of pharmaceutical preparations. The sustained-release tablet comprises a double-layer core and a coating layer; the double-layer core comprises a drug-containing layer and a push layer; wherein the drug-containing layer comprises: tofacitinib citrate, an adhesive, polyethylene oxide, a glidant and a lubricant; the push layer comprises: mannitol, an adhesive, red iron oxide, polyethylene oxide, a glidant and a lubricant; the coating layer comprises: cellulose acetate, a pore-forming agent, a plasticizer, water and acetone. The sustained-release tablet preparation of the present invention solves the technical problems existing in the prior art by adopting a double-layer osmotic pump prescription design, adopting non-hygroscopic materials such as mannitol, adopting a standard round tablet design, preparing a sustained-release coating layer without using methanol, and adopting a coating machine for coating and curing.

The invention discloses an aspirin enteric-coated micro-tablet capsule and a preparation method thereof. The micro-tablet core auxiliary materials of the enteric-coated micro-tablet capsule comprise an excipient, a disintegrating agent, a stabilizer, a flow aid and a lubricant. Tartaric acid is adopted as a stabilizer of aspirin, gel silicon dioxide is adopted as a flow aid, a moisture absorption agent and a swelling agent, and a direct powder tabletting method is adopted to prepare a micro-tablet core; the invention provides the aspirin enteric-coated micro-tablet capsule which is good in powder flowability, stable and easy to control in process, good in stability, uniform in dissolution and release characteristics, stable in blood concentration and high in bioavailability.

The invention provides a nicotine orally disintegrating tablet with a multi-layer composite sustained-release structure and a preparation method of the nicotine orally disintegrating tablet. The nicotine orally disintegrating tablet comprises an inner layer, a middle layer and an outer layer, wherein the middle layer and the outer layer sequentially coat the inner layer from inside to outside; the outer layer comprises nicotine, instant starch and a lubricant; the middle layer comprises nicotine, ethyl cellulose, polyethylene glycol and a flow aid; the inner layer comprises the following components: nicotine nanoparticles coated with chitosan and sodium tripolyphosphate, an oral microenvironment regulator and a filling agent. According to the nicotine orally disintegrating tablet provided by the invention, due to the gradient coating structure design of the inner layer, the middle layer and the outer layer, the multi-stage accurate release of nicotine, namely early-stage quick release, middle-stage stable release and later-stage slow release, is realized, the reactions of dizziness, vomiting and the like caused by excessive release of nicotine are avoided, and the use comfort is improved. Meanwhile, the pH value of the oral cavity is adjusted, micro-ecological balance of the oral cavity is maintained, the content of volatile sulfide in breath is reduced, and breath is refreshed.

The invention relates to the field of pharmaceutical preparations, and particularly discloses an amorphous-state tigorazan tablet and a preparation method thereof. The amorphous-state tigorazan tablet comprises a tablet and a coating material in a weight ratio of 100: (2-4), the tablet comprises the following raw materials: amorphous-state tigorazan, a carrier inclusion material, an excipient, a disintegrating agent, a lubricant and a flow aid, the dosage of the amorphous-state tigorazan is 20-30% of the total mass of all the raw materials of the tablet, and the dosage of the carrier inclusion material is 20-30% of the total mass of all the raw materials of the tablet. The weight ratio of the amorphous tigoran to the carrier inclusion material is 1: (0.80-1.15), and the carrier inclusion material is vitamin E polyethylene glycol succinate. The amorphous tigorazan tablet provided by the invention not only has higher solubility and dissolution rate, but also has higher stability and better hardness and friability, not only improves the bioavailability of drugs, but also avoids the use of organic solvents, simplifies the production process, reduces the risks of production safety and environmental protection, and is suitable for large-scale industrial production.

A pharmaceutical composition comprising: (a) from about 1 to about 25 wt% AZD0780; (b) from about 60 to about 95 wt% of two or more pharmaceutical diluents; (c) from about 3 to about 5 wt% of one or more pharmaceutical disintegrants; (d) from about 0.5 to about 3 wt% of one or more pharmaceutical lubricants; (e) from 0.0 to about 5 wt% of one or more pharmaceutical glidants; and (f) from 0.0 to about 5 wt% of one or more pharmaceutical binders, wherein the component weights add up to 100 and a method of lowering LDL-C levels, reducing cardiovascular risk and / or treatment of a cardiovascular disease, comprising administering to a subject in need thereof AZD0780, or a pharmaceutically acceptable salt thereof, in a daily dose of from 1 mg to 30 mg.

The invention relates to a Canbustine tablet and a preparation method thereof. The Cangbustine tablet comprises a tablet core and a film coating layer coated on the tablet core, the tablet core is prepared from the following raw material components in percentage by weight: 32 to 63.5 percent of an active component, 32 to 48 percent of a filling agent, 4 to 12 percent of a flow aid, 2 to 6 percent of a disintegrating agent and 0.5 to 7 percent of a lubricating agent, wherein the active component is combobustine; the film coating layer is prepared from a film-forming agent, polyethylene glycol, an additive and water, wherein the mass ratio of the film-forming agent to the polyethylene glycol to the additive is (2-6.4): 1: (1.7-5.3). Compared with the prior art, the preparation process is simple, and the obtained combobustine tablet has good dissolution rate, stability and bioequivalence and is easy for industrial production.

The invention discloses an eperisone hydrochloride solid tablet composition and a preparation method thereof, the solid tablet composition contains eperisone hydrochloride, a filler, a disintegrating agent, an adhesive, a flow aid, a lubricant and a coating agent, and the preparation method comprises the following steps: preparing an adhesive aqueous solution; carrying out wet granule preparation, fluidized drying and granule finishing on the internally added materials in a fluidized drying granulator by using the adhesive solution, and mixing, tabletting and coating dry granules with a flow aid and a lubricant; the acidic disintegrating agent is introduced, so that the increase of related substances of the finished product under high temperature, high temperature and high humidity can be remarkably reduced; a fluidized bed is adopted for one-step granulation, and the prepared finished product has good dissolution rate and stability equivalent to that of a reference preparation; the eperisone hydrochloride tablet provided by the invention is stable in quality, simple and feasible in production process, high in controllability and easy for industrial production.

A single-layer tablet comprising linagliptin, or a pharmaceutically acceptable salt thereof, metformin hydrochloride, a diluent, a glidant and a lubricant, wherein the tablet is produced by direct compression.

The invention discloses a tacrolimus-containing pellet pharmaceutical composition, the pharmaceutical composition is composed of an enteric pellet and a sustained-release pellet, the enteric pellet comprises 0.5-5% of tacrolimus, 10-80% of a filler, 2-10% of a disintegrating agent, 1-5% of an adhesive, 0.5-2% of a flow aid, 0.5-1% of a lubricant, and 5-13% of an enteric coating material; the sustained-release pellet comprises 0.5 to 2% of tacrolimus, 10 to 80% of a filling agent, 2 to 10% of a disintegrating agent, 1 to 5% of an adhesive, 0.1 to 1% of a flow aid, 0.1 to 1% of a lubricant, 5 to 15% of a sustained-release coating material and 0.1 to 0.5% of a plasticizer. The pellet pharmaceutical composition containing tacrolimus disclosed by the invention can maintain longer blood concentration and longer action time, so that the medicine taking frequency is reduced, the compliance of a patient is improved, the toxic and side effects are reduced, and the effectiveness and safety of medicine use are further ensured.

The present application belongs to the technical field of oral solid preparation, and particularly relates to a mosapride citrate orally disintegrating tablet and a preparation method thereof. Raw and auxiliary materials comprise mosapride citrate, a filling agent, a disintegrating agent, a glidant, a lubricant and a flavoring agent. The present application screens and optimizes the auxiliary material formula, adopts dry granulation, optimizes the preparation process, improves the compressibility and fluidity of the material, saves energy, improves the production quality and stability, makes the prepared orally disintegrating tablet disintegrate rapidly, has excellent taste, greatly improves the medication compliance of patients, simultaneously improves the drug dissolution and improves the bioavailability. In addition, compared with other types of solid oral preparations of the product, the mosapride citrate orally disintegrating tablet is particularly suitable for the elderly and patients with difficulty in swallowing, and provides convenience in special and urgent situations such as lack of drinking water for taking medicine.

To provide an oral capsule and a method for filling the capsule by directly mixing powders, wherein the oral capsule comprises a composition for an oral capsule and a capsule shell, and the composition for the oral capsule comprises zanubrutinib, a filler, a disintegrant, a wetting agent, a glidant, a lubricant, and an optional binder.SOLUTION: The capsule composition can achieve satisfactory product stability, dissolution properties meeting bioavailability standards, a preparation process consistent with production equipment, and reasonable production costs. Furthermore, the method of the present invention is a non-granulating process, which can simplify the overall process and reduce the impact of the preparation process on product bioavailability.SELECTED DRAWING: None

The invention relates to the technical field of pharmaceutical preparations, in particular to a mesalazine enteric-coated sustained-release tablet and a preparation process thereof. The preparation method comprises the following steps: S1, uniformly mixing mesalazine, a pH regulator, modified hydroxypropyl methyl cellulose, a filler and an adhesive, carrying out wet granulation, drying, carrying out size stabilization, adding a lubricant and a flow aid, uniformly mixing, and tabletting to obtain a tablet core; s2, uniformly mixing hydroxypropyl methyl cellulose and deionized water to obtain an isolation coating solution; spraying the isolation coating liquid onto the tablet core to form an isolation coating layer so as to obtain an isolation coating tablet core; s3, uniformly mixing a methacrylic acid-ethyl acrylate copolymer dispersion liquid, a modified polyacrylate emulsion, an ethanol water solution, Tween 80, a plasticizer and talcum powder to obtain an enteric coating liquid; and spraying the enteric coating liquid onto the isolation coating tablet core to form an enteric coating layer, thereby obtaining the mesalazine enteric sustained-release tablet.

The invention discloses a high-filling high-toughness PP (polypropylene) flame-retardant material and a preparation method thereof, and the high-filling high-toughness PP flame-retardant material comprises the following raw materials in percentage by weight: 45-52% of modified bamboo powder; the total proportion of the PP and the PP-g-MAH is 15%-20%, and the weight ratio of the block copolymerized PP to the PP-g-MAH is (1: 0.5)-(1: 1.5); the proportion of the POE-g-MAH is 10% to 22%; the proportion of the flame retardant is 12.5 to 14.5 percent; the proportion of the antioxidant is 0.4%-0.5%; synergistic and efficient reinforcing and toughening of the high-filling material are achieved, the small-amount and efficient result reserves enough space for increasing the proportion of the flame retardant in a blending system, and therefore high flame retardance of the material is achieved.

The invention provides a pharmaceutical composition containing lamidetan. The pharmaceutical composition comprises lamidetan and / or pharmaceutically acceptable salt thereof, a filler, a disintegrating agent, a lubricant, an adhesive and a flow aid. The composition is good in auxiliary material compatibility, high in preparation stability, less in impurity degradation after being placed under the conditions of high temperature, high humidity and the like, stable in active ingredient crystal form, simple in preparation process, easy to operate and suitable for large-scale industrial production.

The present invention relates to an orodispersible tablet manufactured by a wet granulation method comprising pregabalin or pharmaceutically acceptable salts thereof, at least one disintegrant, at least one diluent, at least one binder, at least one glidant, at least one lubricant, and one or more pharmaceutically acceptable excipients. The orodispersible tablet prepared using these excipients exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. Further, the present invention also relates to the process for preparing the said solid pharmaceutical composition.

The invention provides a lumepirone tosylate capsule as well as a preparation method and application thereof, and belongs to the field of pharmaceutical preparations. The lumepirone tosylate capsule is prepared from the following raw materials and auxiliary materials in percentage by mass: 5%-30% of lumepirone tosylate, 30%-73% of a diluent, 2.5%-15% of a disintegrating agent, 0.5%-5% of a flow aid and 0.2%-2% of a lubricant. The lumepirone tosylate capsule prepared by the invention is good in mixing uniformity, uniform in content and suitable for industrial production.

The present invention discloses a buclizine hydrochloride orally disintegrating tablet composition and a preparation method thereof, which relates to the technical field of preparations. The buclizine hydrochloride orally disintegrating tablet composition, calculated by weight parts, comprises the following components: 4 parts of buclizine hydrochloride fine powder, 60-100 parts of a diluent, 10-30 parts of a disintegrant, 0.5-2 parts of a binder, 1-3 parts of a glidant, 1-5 parts of a sweetening agent, 0.5-5 parts of a lubricant, and 0.5-1.5 parts of a solubilizer. The present invention uses buclizine hydrochloride in combination with a solubilizer, so that the dissolution of buclizine hydrochloride is greatly improved. In combination with other components in the material, low-substituted hydroxypropyl cellulose and cross-linked polyvinylpyrrolidone, the disintegration time limit is further improved.

The invention provides an edaravone dispersible tablet and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations, and the preparation method comprises the following steps: taking 52.5% by weight of edaravone, 0.5-5% by weight of a disintegrating agent, 0.5-5% by weight of a flow aid, 0.5-5% by weight of a sweetening agent, 0.25-5% by weight of a lubricant and the balance of a lactose microcrystalline cellulose co-treatment substance, directly and uniformly mixing, and tabletting to obtain the edaravone dispersible tablet. The lactose and microcrystalline cellulose co-treatment material integrates the advantages of lactose and cellulose, the fluidity and compressibility of total mixed powder can be guaranteed, the tablet weight difference of the tabletting process is reduced, the feasibility of mass production is guaranteed, and the production efficiency and the qualification rate of the tabletting process are improved; compared with a traditional solid dispersion process, the method has the advantages that solvent treatment, fluidized bed granulation or high-temperature drying steps are not needed, and preparation production can be completed only through direct mixing and tabletting processes, so that the influence of a humid and hot environment on the API stability is fundamentally avoided, and the product is more stable.

The invention provides a pharmaceutical composition which comprises a compound shown as a formula I or pharmaceutically acceptable salt and auxiliary materials, the auxiliary materials comprise one or more of a filling agent, an adhesive, a flow aid, a disintegrating agent and a lubricating agent, and the pharmaceutical composition has the advantages of preparation process preparation feasibility, excellent preparation properties, good stability and good dissolution performance and meets the medicinal standard.

The present invention relates to an orodispersible tablet manufactured by a direct compression method comprising Topiramate or pharmaceutically acceptable salts thereof, at least one or more diluents, at least two or more disintegrant, at least one lubricant, at least one glidant, and at least one flavoring agents. The orodispersible tablet prepared using these excipients exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. Further, the present invention also relates to the process for preparing the said Orodispersible tablet.

A pharmaceutical composition containing minoxidil, which is composed of minoxidil, a filler, a sustained-release material, a glidant and a lubricant, wherein the specification of minoxidil is 1.25-5.0 mg, and the sustained-release material is selected from hypromellose. The minoxidil composition has a sustained-release effect of 8-12 hours in vitro, has an ideal in-vivo plasma concentration and bioavailability, and ensures the safety and effectiveness of the use of minoxidil.

The invention provides a high strength neratinib tablet and a method of its manufacturing comprising spraying intragranular components of a granulation comprising neratinib maleate, fillers, disintegrants and glidants, with a surface modifying agent and combining them with extragranular components comprising fillers, disintegrants and lubricants.

The invention discloses a pharmaceutical composition containing meclofenoxate hydrochloride, which is characterized by comprising meclofenoxate hydrochloride, a filling agent, a flow aid, a lubricant, a stabilizer and an antioxidant, the mass ratio of meclofenoxate hydrochloride to the stabilizer to the antioxidant is 1: (0.005-0.015): (0.001-0.005), the mass ratio of meclofenoxate hydrochloride to the filling agent to the flow aid is 1: (0.3-0.7): (0.1-0.5), and the lubricant is a lubricant. The stabilizer is benzoic acid. Benzoic acid is selected as a stabilizing agent, and the hygroscopicity is obviously lower than that of citric acid, in RHlt; and when the content is 80%, moisture is not absorbed basically, so that the meclofenoxate hydrochloride is effectively prevented from being hydrolyzed due to moisture absorption.

The present invention provides a composition of nebivolol and amlodipine, comprising nebivolol, amlodipine and a pharmaceutical excipient. The nebivolol comprises one or more of nebivolol, a pharmaceutically acceptable salt thereof, and a solvate thereof. The amlodipine comprises one or more of amlodipine, a pharmaceutically acceptable salt thereof, and a solvate thereof. The pharmaceutical excipient is selected from one or more of a filler, a binder, a disintegrant, a lubricant, and a glidant. The composition does not contain a colorant and a film coating. The compound preparation of the present invention has good stability, and is beneficial to improving the antihypertensive efficacy, enhancing safety and tolerability, and reducing side effects. Compared to monotherapy, the present invention reduces the number of administered medications and improves the compliance of patients, is beneficial to improving the medication compliance of the elderly patients and individuals with dysphagia, maintains a stable plasma drug concentration, maintains long-term stable blood pressure in hypertensive patients, prevents the patients from discontinuing medication arbitrarily, and prevents disease recurrence and the progression of severe complications.

The present invention provides a composition with a solubilizing effect, a preparation method thereof, and an application thereof. The composition comprises a solubilizing agent, a glidant, and an inclusion compound, wherein the mass ratios of the components are as follows: the mass ratio of the solubilizing agent to the inclusion compound is 1:1-1:20, and the mass ratio of the glidant to the inclusion compound is 1:100-3:20. The composition of the present invention can effectively improve the solubility of macrolides, tetracyclines, and penicillins, and the composition of the present invention does not react with the active ingredients of the drugs, ensuring that after the drugs are mixed therewith, the active ingredients of the drugs are stable, and the mixture of the drugs and the composition does not agglomerate or discolor.

A pharmaceutical composition, and a preparation method therefor and the use thereof. The pharmaceutical composition contains: (4aR,8R)-3-acryloyl-11-chloro-10-(2-fluoro-6-hydroxyphenyl)-8-(2-isopropyl-4-methylpyridin-3-yl)-6-methyl-2,3,4,4a,6,8-hexahydro-1H-pyrazino[1′,2′:4,5]pyrazino[2,3-c][1,8]naphthyridin-5,7-dione or a pharmaceutically acceptable salt thereof as an active ingredient; and one or more selected from a filler, a disintegrant, a lubricant, a glidant and a binder. The pharmaceutical composition has good stability and drug dissolution, and the preparation process is simple and is suitable for industrial production.

The application belongs to the technical field of pharmaceutical preparations, and particularly relates to a roxithromycin preparation and a preparation method thereof. The roxithromycin preparation is prepared from the following raw materials: roxithromycin, a stabilizer, a glidant, a filler, a binder and a lubricant. The stabilizer is a mixture of hydroxypropyl methyl cellulose and povidone. The glidant is talc. The stabilizer system used in the traditional high-pressure homogenization technology (HPH) is optimized according to the particularity of the roxithromycin raw material. The hydroxypropyl methyl cellulose and the povidone are used together, and the talc is introduced to improve the powder properties of the prepared nanocrystals, so that the subsequent production and manufacturing are facilitated. The preparation prepared according to the method has stable drug quality and accurate dosage.

The present invention discloses a new formulation composition of apixaban with obvious clinical advantages and a preparation method thereof, belonging to the field of pharmaceutical preparations. The new formulation composition of apixaban comprises the following components: apixaban, a filler, a binder, a disintegrant, a solubilizer, a glidant, a lubricant and a flavoring agent; wherein, the binder is hydroxypropyl cellulose, and calculated by weight percentage, the proportion of the binder is 1.0-3.0%. The new formulation composition of apixaban provided by the present invention has a short disintegration time in the oral cavity and does not need to be swallowed with water, thereby improving the convenience and compliance of administration, improving the medication safety of special populations, and providing a better choice for patients with dysphagia and / or those who need to crush tablets and then take them orally or by nasogastric feeding after surgery.